文献速递腹部技术与安全US

肝细胞癌监测超声的超声LI-RADS可视化评分:系统综述与Meta分析

Ultrasound LI-RADS Visualization Scores on Surveillance Ultrasound for Hepatocellular Carcinoma: A Systematic Review With Meta-analysis.
PubMed 文献 · Ultrasound Med Biol · 2023-07-28

该系统综述与Meta分析汇总12项研究共25,698次监测超声检查,基于超声LI-RADS评估可视化评分分布:A、B、C评分的合并比例分别为56.7%、30.3%和6.9%。肝硬化、非酒精性脂肪性肝病及体重指数>25 kg/m2的研究中可视化评分C比例更高。

要点

  • 监测超声中可视化评分C(严重受限)合并比例为6.9%,评分B为30.3%。
  • 仅纳入肝硬化患者及病因为非酒精性脂肪性肝病的研究中,评分C比例显著更高(p<0.05)。
  • 平均或中位体重指数>25 kg/m2的研究中,评分C合并比例为10.7%。

核心结论

  • 相当比例的监测超声检查存在中度至重度可视化限制,肝硬化、非酒精性脂肪性肝病和肥胖患者中超声LI-RADS可视化评分C的比例似乎更高。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE和EMBASE(2017年1月1日至2022年11月25日),纳入12项报告超声LI-RADS可视化评分的研究,共25,698次超声检查;采用DerSimonian-Laird随机效应模型计算合并比例,并进行亚组Meta回归分析。

诊断标准与关键数值

  • 超声LI-RADS可视化评分A的合并比例为56.7%(95%CI:38.6-73.2%,I²=99.2%)。
  • 超声LI-RADS可视化评分B的合并比例为30.3%(95%CI:21.5-40.7%,I²=98.8%)。
  • 超声LI-RADS可视化评分C的合并比例为6.9%(95%CI:3.9-11.7%,I²=97.7%)。
  • 仅纳入肝硬化患者的研究及病因为非酒精性脂肪性肝病的研究中,可视化评分C比例显著更高(p<0.05)。
  • 平均或中位体重指数>25 kg/m2的研究中,可视化评分C合并比例为10.7%(95%CI:4.3-24.3%)。

局限性

  • 各可视化评分合并比例的异质性很高(评分A的I²=99.2%,评分B的I²=98.8%,评分C的I²=97.7%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

We performed a systematic review and meta-analysis to determine the proportions of each surveillance ultrasound (US) visualization score for hepatocellular carcinoma based on the US Liver Imaging Reporting and Data System (LI-RADS) and to identify the factors associated with visualization score C. Original publications reporting US LI-RADS visualization scores were identified in MEDLINE and EMBASE from January 1, 2017, to November 25, 2022. The meta-analytic pooled proportion of each visualization score based on US examination was calculated using the DerSimonian‒Laird random-effects model. Subgroup meta-regression analyses were performed to explore study heterogeneity. US LI-RADS visualization scores were reported from a total of 25,698 US examinations across 12 studies. The pooled proportions of visualization scores A, B and C were 56.7% (95% confidence interval [CI]: 38.6-73.2%, I2 = 99.2%), 30.3% (95% CI: 21.5-40.7%, I2 = 98.8%) and 6.9% (95% CI: 3.9-11.7%, I2 = 97.7%), respectively. Significantly higher proportions of visualization score C were found in studies that exclusively enrolled cirrhosis patients and a study in which the disease etiology was non-alcoholic fatty liver disease (NAFLD) (p < 0.05). In addition, the pooled proportion of visualization score C was higher in studies with a mean or median body mass index >25 kg/m2 (10.7%, 95% CI: 4.3-24.3%). In conclusion, a substantial proportion of surveillance US examinations exhibited moderate to severe limitations on visualization. There was a tendency toward higher proportions of US LI-RADS visualization score C in patients with cirrhosis, NAFLD and obesity.

来源:Ultrasound Med Biol,查看原文。版权归原作者所有。

引用

  1. Kang JH, Kim NH, Kim DH, et al. Ultrasound LI-RADS Visualization Scores on Surveillance Ultrasound for Hepatocellular Carcinoma: A Systematic Review With Meta-analysis. Ultrasound Med Biol. 2023. PMID: 37517886. doi:10.1016/j.ultrasmedbio.2023.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。